P2X7 receptor antagonists: a patent review (2010–2015)

References

• North RA, Barnard EA. Nucleotide receptors. Curr Opin Neurobiol. 1997;7:346–357.
   PubMed Web of Science ®Google Scholar
• Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413–492.
   PubMed Web of Science ®Google Scholar
• Surprenant A, Rassendren F, Kawashima E, et al. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272(5262):735–738.
   PubMed Web of Science ®Google Scholar
• Yu Y, Ugawa S, Ueda T, et al. Cellular localization of P2X7 receptor mRNA in the rat brain. Brain Res. 2008;1194:45–55.
   PubMed Web of Science ®Google Scholar
• Collo G, Neidhart S, Kawashima E, et al. Tissue distribution of the P2X7 receptor. Neuropharmacology. 1997;36(9):1277–1283.
   PubMed Web of Science ®Google Scholar
• Denlinger LC, Fisette PL, Sommer JA, et al. Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J Immunol. 2001;167(4):1871–1876.
   PubMed Web of Science ®Google Scholar
• Costa-Junior HM, Sarmento Vieira F, Coutinho-Silva R. C terminus of the P2X7 receptor: treasure hunting. Purinergic Signal. 2011;7(1):7–19.
   PubMed Web of Science ®Google Scholar
• Kawate T, Michel JC, Birdsong WT, et al. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature. 2009;460(7255):592–598.
   PubMed Web of Science ®Google Scholar
• Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012;485(7397):207–213.
   PubMed Web of Science ®Google Scholar
• Alzola E, Pérez-Etxebarria A, et al. Activation by P2X7 agonists of two phospholipases A2 (PLA2) in ductal cells of rat submandibular gland. Coupling of the calcium-independent PLA2 with kallikrein secretion. J Biol Chem. 1998;273(46):30208–30217.
   PubMed Web of Science ®Google Scholar
• Pochet S, Gómez-Muñoz A, Marino A, et al. Regulation of phospholipase D by P2X7 receptors in submandibular ductal cells. Cell Signal. 2003;15(10):927–935.
   PubMed Web of Science ®Google Scholar
• Kahlenberg JM, Dubyak GR. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol. 2004;286(5):C1100–8.
   PubMed Web of Science ®Google Scholar
• Donnelly-Roberts DL, Namovic MT, Faltynek CR, et al. Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells. J Pharmacol Exp Ther. 2004;308(3):1053–1061.
   PubMed Web of Science ®Google Scholar
• Korcok J, Raimundo LN, Ke HZ, et al. Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. J Bone Miner Res. 2004;19(4):642–651.
   PubMed Web of Science ®Google Scholar
• Verhoef PA, Estacion M, Schilling W, et al. P2X7 receptor-dependent blebbing and the activation of rho-effector kinases, caspases, and IL-1 release. J Immunol. 2003;170:5728–5738.
   PubMed Web of Science ®Google Scholar
• Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. Embo J. 2006;25:5071–5082.
   PubMed Web of Science ®Google Scholar
• Locovei S, Scemes E, Qiu F, et al. Pannexin 1 is part of the pore forming unit of the P2X7 receptor death complex. FEBS Lett. 2007;581:483–488.
   PubMed Web of Science ®Google Scholar
• Iglesias R, Locovei S, Roque A, et al. P2X7 receptor-pannexin 1 complex: pharmacology and signaling. Am J Physiol Cell Physiol. 2008;295(3):C752–C760.
   Google Scholar
• Alberto AV, Faria RX, Couto CGC, et al. Is pannexin the pore associated with the P2X7 receptor? Naunyn Schmiedebergs Arch Pharmacol. 2013;386(9):775–787.
   PubMed Web of Science ®Google Scholar
• Pelegrin P. Targeting Interleukin-1 signaling in chronic inflammation: focus on P2X7 receptor and Pannexin-1. Drug News Perspect. 2008;21:24–33.
   Google Scholar
• Weber A, Wasiliew P, Kracht M, et al. Interleukin-1β (IL-1β) processing pathway. Sci Signal. 2010;19:CM2.
   Google Scholar
• Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176:3877–3883.
   PubMed Web of Science ®Google Scholar
• Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386–396.
   PubMed Web of Science ®Google Scholar
• Basso AM, Bratcher NA, Harris RR, et al. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res. 2009;198(1):83–90.
   PubMed Web of Science ®Google Scholar
• Csölle C, Andó RD, Kittel Á, et al. The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. Int J Neuropsychopharmacol. 2013;16(1):213–233.
   PubMed Web of Science ®Google Scholar
• Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013;9(4):491–540.
   PubMed Web of Science ®Google Scholar
• Ren S, Zhang Y, Wang Y, et al. Targeting P2X₇ receptor inhibits the metastasis of murine P388D1 lymphoid neoplasm cells to lymph nodes. Cell Biol Int. 2010;34(12):1205–1211.
   PubMed Web of Science ®Google Scholar
• Gu LQ, Li FY, Zhao L, et al. Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine. 2010;38(2):276–282.
   PubMed Web of Science ®Google Scholar
• Jelassi B, Anchelin M, Chamouton J, et al. Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis. 2013;34(7):1487–1496.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Li WH, Zhang H-Q, et al. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One. 2014;9(12):e114371.
   PubMed Web of Science ®Google Scholar
• Xia J, Yu X, Tang L, et al. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep. 2015;34(1):103–110.
   PubMed Web of Science ®Google Scholar
• AZD9056. Bethesda MD: National Center for Advancing Translational Sciences (NCATS); 2011. Available from http://ncats.nih.gov/files/AZD9056.pdf
   Google Scholar
• Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71(10):1630–1635.
   PubMed Web of Science ®Google Scholar
• Pfizer CE-224535/P2X7 Receptor Antagonist. Bethesda MD: National Center for Advancing Translational Sciences (NCATS); 2011. Available from https://ncats.nih.gov/files/CE-224535.pdf
   Google Scholar
• Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012;39(4):720–727.
   PubMed Web of Science ®Google Scholar
• Evotec grants exclusive rights on EVT 401 in China to conba pharmaceutical. United Kingdom: Evotec Ltd; 2012. Available from https://www.evotec.com/article/en/Press-releases/Evotec-grants-exclusive-rights-on-EVT-401-in-China-to-Conba-Pharmaceutical/2274
   Google Scholar
• Studies filtered by compound GSK1482160. United Kingdom: GlaxoSmithKline plc; 2009. Available from http://www.gsk-clinicalstudyregister.com/compounds/gsk1482160#ps
   Google Scholar
• AFC-5128. New York (NY): Torreya Insights, LLC; 2011. Available from http://www.avarx.com/search/showOpportunityDetails?asset_id=1440
   Google Scholar
• GSK. Imidazolidine carboxamide derivatives as P2X7 modulators. US20100075968 (2010)
   Google Scholar
• GSK. Thiadiazolidinedioxide P2X7 receptor antagonists. WO2011054947 (2011)
   Google Scholar
• GSK. Pyrazole derivatives as P2X7 modulators. US20110046137 (2011)
   Google Scholar
• GSK. 4-benzoyl-1-substituted-piperazin-2-one derivatives as P2X7 modulators. US20100311749 (2010)
   Google Scholar
• GSK. 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyrazine derivatives as P2X7 modulators. US20120157436 (2012)
   Google Scholar
• AstraZeneca. Quinoline derivatives 057. US8106073 (2012)
   Google Scholar
• AstraZeneca. Compounds 679. US7964616 (2011)
   Google Scholar
• Roche. Dihydropyrimidone amides as P2X7 modulators. US20110028502 (2011)
   Google Scholar
• Roche. [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators. US20110071143 (2011)
   Google Scholar
• Roche. Amido compounds. US20120149718 (2012)
   Google Scholar
• Roche. Isoindolyl compounds. US20120157494 (2012)
   Google Scholar
• Janssen Pharmaceutica. Quinoline or isoquinoline substituted P2X7 antagonists. US20110092481 (2011)
   Google Scholar
• Janssen Pharmaceutica. 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators. US20140275056 (2014)
   Google Scholar
• Janssen Pharmaceutica. P2X7 modulators. US20140275120 (2014)
   Google Scholar
• Janssen Pharmaceutica. [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators. US20140275096 (2014)
   Google Scholar
• Actelion pharmaceuticals Ltd. Benzamide derivatives as P2X7 receptor antagonists. WO2012114268 (2012)
   Google Scholar
• Actelion pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists. US20140163035 (2014)
   Google Scholar
• Actelion pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists. US20150025075 (2015)
   Google Scholar
• Actelion pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists. WO2014097140 (2014)
   Google Scholar
• H. LUNDBECK A/S. Heteroaryl amide analogues. US20120190680 (2012)
   Google Scholar
• H. LUNDBECK A/S. Heteroaryl amide derivatives. US20120172366 (2013)
   Google Scholar
• H. LUNDBECK A/S. Heteroaryl amide analogues as P2X7 antagonists. US8580812 (2013)
   Google Scholar
• H. LUNDBECK A/S. Benzamides. WO2014057078 (2014)
   Google Scholar
• H. LUNDBECK A/S. N-(2-(cyclic amine)ethyl)benzamide derivatives as P2X7 inhibitors. WO2014057080 (2014)
   Google Scholar
• Renovis, INC. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof. US20100184802 (2010)
   Google Scholar
• Renovis, INC. Novel compounds as P2X7 modulators and uses thereof. US20100022531 (2010)
   Google Scholar
• Abbott. P2X7 receptor antagonists and methods of use. US7709469 (2010)
   Google Scholar
• Abbott. Amino-tetrazoles analogues and methods of use. US7723367 (2010)
   Google Scholar
• Nissan chemical industries, Ltd. Pyridazinone compounds and P2X7 receptor inhibitors. US20100286390 (2010)
   Google Scholar
• Aventis Pharmaceuticals, Inc. Heterocyclic compounds as P2X7 ion channel blockers. US7741493 (2010)
   Google Scholar
• Pfizer Product Inc. Benzamide and heteroarylamide as P2X7 receptor antagonists. EP1448535 (2011)
   Google Scholar
• Schering corp. Triazolopyrazinones as P2X7 receptor antagonists. WO2012040048 (2012)
   Google Scholar
• AXXAM S.P.A. Substituted thiazole or oxazole P2X7 receptor antagonists. WO2015118019 (2015)
   Google Scholar
• Biosceptre International, Ltd. Hybridomas producing antibodies against nonfunctional P2X7 receptor. US20100105068 (2010)
   Google Scholar
• Biosceptre International, Ltd. Combination therapy. US20150004179 (2015)
   Google Scholar
• Abbott. P2X7 antagonists to treat affective disorders. US20110269708 (2011)
   Google Scholar
• Royal College of Surgeons in Ireland. P2X7 antagonists as frontline or adjunctive treatment against status epilepticus. EP2604265 (2013)
   Google Scholar
• Jackson Alexander. Imaging the central nervous system with purinergic P2X7 receptor binding agents. US20120034165 (2012)
   Google Scholar
• Cornell Research Foundation, Inc. Purine receptor inhibition as a therapeutic strategy in spinal cord and brain. US7923448 (2011)
   Google Scholar
• University Hospitals of Cleveland. P2X7: Inhibition of epithelial cancers and papillomas. US20140037576 (2014)
   Google Scholar
• Claire Mitchell. Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors. US20120264708 (2012)
   Google Scholar
• Kaleko Michael. Therapies for disorders of the cornea and conjunctiva. US20140322193 (2014)
   Google Scholar
• Astellas Pharma Inc. Therapeutic agent for fatty liver disease containing P2X7 receptor inhibitory substance as active ingredient. WO2012036193 (2012)
   Google Scholar
• UCL Business Plc. P2X7 receptor agonist for use in preventing or treating kidney injury. WO2014174282 (2014)
   Google Scholar
• Miras Portugal. Use of P2X7 receptor antagonists to promote axonal growth and ramification. WO2010018280 (2010)
   Google Scholar
• Ali Z, Laurijssens B, Ostenfeld T, et al. Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin Pharmacol. 2013;75(1):197–207.
   PubMed Web of Science ®Google Scholar
• Eser A, Colombel J-F, Rutgeerts P, et al. Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active crohn’s disease: a randomized placebo-controlled, double-blind, phase IIa study. Inflamm Bowel Dis. 2015;21(10):2247–2253.
   PubMed Web of Science ®Google Scholar
• Kurashima Y, Amiya T, Nochi T, et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun. 2012;3:1034.
   PubMed Web of Science ®Google Scholar
• Sorge RE, Trang T, Dorfman R, et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012;18(4):595–599.
   PubMed Web of Science ®Google Scholar
• Ying YL, Wei XH, Xu X-B, et al. Over-expression of P2X7 receptors in spinal glial cells contributes to the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR) in rats. Exp Neurol. 2014;261:836–843.
   PubMed Web of Science ®Google Scholar
• Bravo D, Maturana CJ, Pelissier T, et al. Interactions of pannexin 1 with NMDA and P2X7 receptors in central nervous system pathologies: Possible role on chronic pain. Pharmacol Res. 2015;101:86–93.
   PubMed Web of Science ®Google Scholar
• Takenouchi T, Sekiyama K, Sekigawa A, et al. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch Immunol Ther Exp (Warsz). 2010;58(2):91–96.
   PubMed Web of Science ®Google Scholar
• Janssen B, Vugts DJ, Funke U, et al. Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [11C]A-740003 as a novel tracer of neuroinflammation. J Labelled Comp Radiopharm. 2014;57(8):509–516.
   PubMed Web of Science ®Google Scholar
• Henshall DC, Engel T. P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus. Epilepsy Behav. 2015;49:8–12.
   PubMed Web of Science ®Google Scholar
• Iwata M, Ota KT, et al. Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2x7 receptor. Biol Psychiatry. 2015;80(1):12–22.
   Web of Science ®Google Scholar
• Gao M, Wang M, Green MA, et al. Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X7 receptor. Bioorg Med Chem Lett. 2015;25(9):1965–1970.
   PubMed Web of Science ®Google Scholar
• Letavic MA, Lord B, Bischoff F, et al. Synthesis and pharmacological characterization of two novel, brain penetrating P2X7 antagonists. ACS Med Chem Lett. 2013;4(4):419–422.
   PubMed Web of Science ®Google Scholar
• Lord B, Ameriks MK, Wang Q, et al. A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. Eur J Pharmacol. 2015;765:551–559.
   PubMed Web of Science ®Google Scholar
• Rudolph DA, Alcazar J, et al. Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorg Med Chem Lett. 2015;25(16):3157–3163.
   PubMed Web of Science ®Google Scholar
• Lord B, Aluisio L, et al. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. J Pharmacol Exp Ther. 2014;351(3):628–641.
   PubMed Web of Science ®Google Scholar
• Chrovian CC, Soyode-Johnson A, et al. Novel phenyl-substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists with robust target engagement in rat brain. ACS Chem Neurosci. 2016;7(4):490–497.
   PubMed Web of Science ®Google Scholar
• Ziff J, Rudolph DA, Stenne B, et al. Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 antagonists. ACS Chem Neurosci. 2016;7(4):498–504.
   PubMed Web of Science ®Google Scholar